$130 Million

Oncopeptides AB

PIPE

Bookrunner, March 2021

Oncopeptides AB
Directed Share Issue

Oncopeptides is a global biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases.The U.S. Food and Drug Administration has recently granted PEPAXTO (melphalan flufenamide, also known as melflufen), accelerated approval in relapsed or refractory multiple myeloma. Melphalan flufenamide is the first drug originated from the Company´s proprietary PDC-platform and is evaluated in a comprehensive clinical study program, including the ongoing phase 3 OCEAN study.